Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 16/20 | 1.00 |
| ▸ | LCP2 | Q13094 | 5/20 | 0.78 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.72 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23988029 | 1.00 | MAP4K1 (1.00) | MAP4K1LCP2RPS6KA2PRKD2 | |
| SCHEMBL30136144 | 1.00 | MAP4K1 (1.00) | MAP4K1LCP2RPS6KA2PRKD2 | |
| SCHEMBL23988032 | 1.00 | MAP4K1 (1.00) | MAP4K1LCP2RPS6KA2PRKD2 | |
| SCHEMBL30233164 | 0.91 | MAP4K1 (0.84) | MAP4K1LCP2RPS6KA2PRKD2 | |
| SCHEMBL25099392 | 0.91 | MAP4K1 (0.84) | MAP4K1LCP2RPS6KA2PRKD2 | |
| SCHEMBL25100176 | 0.88 | LCP2 (1.00) | MAP4K1LCP2RPS6KA2PRKD2 | |
| SCHEMBL30136158 | 0.88 | LCP2 (1.00) | MAP4K1LCP2RPS6KA2PRKD2 | |
| SCHEMBL23988028 | 0.88 | LCP2 (1.00) | MAP4K1LCP2RPS6KA2PRKD2 | |
| SCHEMBL25099340 | 0.87 | LCP2 (0.91) | MAP4K1LCP2RPS6KA2PRKD2 | |
| SCHEMBL25099429 | 0.87 | LCP2 (0.91) | MAP4K1LCP2RPS6KA2PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197703-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | MAP4K1 108/4885LCP2 4392/4885RPS6KA2 109/4885 |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | MAP4K1 108/4885LCP2 4392/4885RPS6KA2 109/4885 |
| US-20240197703-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | MAP4K1 108/4885LCP2 4392/4885RPS6KA2 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.